Inhibition of MR signaling with MR antagonists has previously shown clinical efficacy in Duchenne muscular dystrophy (DMD) cardiomyopathy and preclinical efficacy in skeletal muscle in DMD models. The gene discussed is NR3C2; the disease is cardiomyopathy.